Purpose: The purpose of this study is to see how safe and effective SER-262 is compared to a placebo, a capsule containing no active drug, in keeping Clostridium difficile infection (C-Diff) from coming back in people who have recovered from a first episode of C-Diff.
Sponsor: Seres Therapeutics, Inc.
Contact: Dr. Weinstock's study coordinator Kelly Moushey at Sundance Clinical Research: 314-567-3377.
This is a compassionate medicine program for patients with either: severe acid reflux, gastroparesis, small intestinal pseudoobstruction, or constipation. Patients who have these conditions and have not responded to other available medicines are able to get this promotility medicine. The company pays for the medicine. The patients are responsible for the clinical follow up, blood tests and EKG tests during the years of treatment.
Study open for people with chronic constipation or irritable bowel syndrome with constipation – call our research nurses 314-567-3377 – open study for those who wish to start an FDA approved medication called Linzess to monitor for safety labs.